Eli Lilly Expanding In India
US pharmaceutical major Eli Lilly is expanding its Asian operations in India. Currently, the company's Asian operations are concentrated in Japan and China.
A spokesman for the company has said that Lilly "saw significant growth in the Asian region last year," and sees India as a country where "we have real opportunities for growth." Henceforth, Lilly will be using India as a gateway to enter the fast-developing Asian pharmaceutical market. Lilly's sales in the Asia-Pacific region are said to have grown 44%, compared with a total international sales growth of 17%.
Lilly has already set up two joint ventures with Ranbaxy Laboratories, India's second-largest drug company, in India and the USA (Marketletter January 30), involving total investments of $90 million or more. And earlier this month it was announced that Rhone-Poulenc Rorer had set up Indian affiliate (Marketletter March 13).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze